NCT04982432View on ClinicalTrials.gov

Orismilast for the Treatment of Mild to Severe Hidradenitis Suppurativa

PHASE2UnknownINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

December 1, 2022

Study Completion Date

December 1, 2022

Conditions

Hidradenitis Suppurativa

Interventions

DRUG

Orismilast

Orismilast is a next generation PD4 inhibitor with demonstrated broad anti inflammatory properties

Sponsors

Collaborators (1)

UNION therapeutics

All Listed Sponsors

collaborator

UNION therapeutics

INDUSTRY

lead

Gregor Jemec

OTHER

NCT04982432 - Orismilast for the Treatment of Mild to Severe Hidradenitis Suppurativa | Biotech Hunter | Biotech Hunter